BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
More: FinSMEs, Endpoints News, Fierce Biotech, BioSpace, GEN - Genetic Engineering and Biotechnology News, American Chemical Society, GeekWire, BrainChild Bio, Inc.
- FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
-
Endpoints News / Kyle LaHucik: BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
- Also at: Fierce Biotech, BioSpace, GEN - Genetic Engineering and Biotechnology News, American Chemical Society, GeekWire, BrainChild Bio, Inc.